Lead Product(s): 67Cu-Sartate
Therapeutic Area: Oncology
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
ODD status may provide a range of advantages for the development of SARTATETM for neuroblastoma treatment.